{
    "clinical_study": {
        "@rank": "131044", 
        "arm_group": [
            {
                "arm_group_label": "Picato\u00ae 0.05% gel", 
                "arm_group_type": "Active Comparator", 
                "description": "once daily for two consecutive days"
            }, 
            {
                "arm_group_label": "ingenol mebutate vehicle formulation 1", 
                "arm_group_type": "Experimental", 
                "description": "once daily for two consecutive days"
            }, 
            {
                "arm_group_label": "ingenol mebutate vehicle formulation 2", 
                "arm_group_type": "Experimental", 
                "description": "once daily for two consecutive days"
            }, 
            {
                "arm_group_label": "ingenol mebutate vehicle formulation 3", 
                "arm_group_type": "Experimental", 
                "description": "once daily for two consecutive days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if the new vehicle formulations containing ingenol\n      mebutate are as safe and effective as Picato\u00ae gel 0.05% (it's current vehicle formulation)\n      when applied to AK lesions on the forearm for two consecutive days."
        }, 
        "brief_title": "Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study will be run in 2 parts.  The first part involves applying escalating\n      concentrations of the new vehicle formulations containing ingenol mebutate to AKs on the\n      forearms.  Reactions and safety will be compared to Picato\u00ae  (a registered and marketed\n      ingenol  mebutate gel) to ascertain if the new vehicle formulations are at least as safe and\n      effective as Picato\u00ae .  The purpose of part 2 is to select the concentration in the \"new\n      formulation\" that produces this same, if not better response, as Picato\u00ae and with a similar\n      or better safety profile."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must be male or female and at least 18 years of age.\n\n          -  Female patients must be of non-childbearing potential or if of childbearing potential\n             then negative serum and urine pregnancy test and using effective contraception.\n\n          -  Ability to provide informed consent.\n\n        Exclusion Criteria:\n\n          -  location of the selected treatment area within 5cm of an incompletely healed wound or\n             within 5cm of a suspected basal cell carcinoma or squamous cell carcinoma\n\n          -  undergone Cosmetic or therapeutic procedures within 2cm of the selected treatment\n             area in the 2 weeks prior to the treatment visit\n\n          -  presence of sunburn within the selected treatment areas\n\n          -  use of acid-containing therapeutic products within 2cm of the selected treatment area\n             in the 2 weeks prior to the treatment visit\n\n          -  previous enrolment in this clinical trial\n\n          -  prior treatment with ingenol mebutate on the forearms\n\n          -  use of topical moisturisers/creams/lotions, artificial tanners or topical steroids\n             within 2cm of the selected treatment areas in the 2 weeks prior to the treatment\n             visit\n\n          -  treatment with immunomodulators, or interferon/interferon inducers or systemic\n             medications that suppress the immune system within 4 weeks of the treatment visit\n\n          -  treatment with 5-FU, imiquimod, diclofenac,or photodynamic therapy within 2 cm of the\n             treatment area in the 8 weeks prior to the treatment visit\n\n          -  use of systemic retinoids\n\n          -  those who are currently participating in any other clinical trial\n\n          -  females who are pregnant or are breastfeeding\n\n          -  those known or suspected or not being able to comply with the requirements of the\n             protocol or provide consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "76", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01803477", 
            "org_study_id": "LP0085-1000"
        }, 
        "intervention": {
            "arm_group_label": [
                "Picato\u00ae 0.05% gel", 
                "ingenol mebutate vehicle formulation 1", 
                "ingenol mebutate vehicle formulation 2", 
                "ingenol mebutate vehicle formulation 3"
            ], 
            "intervention_name": "once daily for two consecutive days (Picato)", 
            "intervention_type": "Drug", 
            "other_name": [
                "Picato\u00ae 0.05% gel", 
                "escalating doses of ingenol mebutate vehicle formulation 1", 
                "escalating doses of ingenol mebutate vehicle formulation 2", 
                "escalating doses of ingenol mebutate vehicle formulation 3"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 24, 2013", 
        "link": [
            {
                "description": "LEO Pharma", 
                "url": "http://www.leopharma.com"
            }, 
            {
                "description": "Therapeutic Goods Administration", 
                "url": "http://www.tga.gov.au"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Woolloongabba", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4102"
                    }, 
                    "name": "Specialist Connect"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Woolloongabba", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4102"
                    }, 
                    "name": "Dermatology Department"
                }
            }
        ], 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Seamless Phase 1/2 Exploratory Multi-centre, Investigator-blind, Dose Escalation Study (Study Part 1), Followed by a Randomised, Intra-subject, Active Controlled Efficacy Study of Different Ingenol Mebutate Formulations Applied to the Forearm for 2 Consecutive Days (Study Part 2)", 
        "other_outcome": {
            "description": "Safety data to be collected via CRF entries of AEs/SAEs and photographs. Treatment responses assessed by Reflective confocal microscopy scoring of visible selected AK lesions", 
            "measure": "Safety of the new ingenol mebutate vehicle formulation (ascertained in Part 1) compared to Picato\u00ae gel applied topically once daily for 2 consecutive days to 4 separate treatment areas containing actinic keratosis on the forearm", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "overall_official": [
            {
                "affiliation": "Specialist Connect", 
                "last_name": "Lynda Spelman, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Dermatology Department, Princess Alexandra Hospital", 
                "last_name": "Hans P Soyer, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Australia: National Health and Medical Research Council", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety data to be collected via CRF entries of AEs/SAEs and photographs. Relative skin reactions for comparison to Picato\u00ae.", 
            "measure": "Safety of 3 new vehicle formulations containing ingenol mebutate compared to Picato\u00ae gel applied topically once daily for two consecutive days to four separate treatment areas containing actinic keratosis on the forearm", 
            "safety_issue": "Yes", 
            "time_frame": "2 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01803477"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Assessed by visible and imaged lesion count", 
            "measure": "Evaluate treatment responses on AK of selected concentration of ingenol mebutate containing vehicle formulation from Part 1 compared to Picato\u00ae gel as assessed by reduction in the number of selected AK lesions 2 months after treatment", 
            "safety_issue": "No", 
            "time_frame": "2 months"
        }, 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}